Does a new diabetes shot protect the heart and kidneys better than an older one?
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested two diabetes drugs — one new (tirzepatide) and one older (dulaglutide) — to see which one better prevents heart attacks, strokes, kidney failure, and death in people with diabetes and heart disease.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 574 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested two diabetes drugs — one new (tirzepatide) and one older (dulaglutide) — to see which one better prevents heart attacks, strokes, kidney failure, and death in people with diabetes and heart disease.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 574 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, Pavo I, Cariou B, Nicholls SJ
Related Content
Claims (6)
In patients with type 2 diabetes and heart disease, tirzepatide lowers the combined risk of serious heart and kidney events by 16% compared to dulaglutide.
In adults with type 2 diabetes and heart disease, tirzepatide is associated with a 16% lower risk of death from any cause over about four years compared to dulaglutide.
In adults with type 2 diabetes and existing heart disease, tirzepatide and dulaglutide show similar rates of stroke over nearly four years of follow-up, with no statistically significant difference between the two drugs.
In adults with type 2 diabetes and heart disease, a weekly injection of tirzepatide lowers the risk of serious heart and kidney events—such as heart attack, stroke, hospitalization for heart failure, or worsening kidney disease—by 16% compared to another drug called dulaglutide, when used for about 4 years.
In adults with type 2 diabetes and cardiovascular disease, tirzepatide lowers the combined risk of serious kidney outcomes—including worsening protein in the urine, significant decline in kidney function, need for dialysis, or death from kidney disease—by 21% compared to dulaglutide.